UNSPSC 51385702: Nimesulide

This classification denotes a cyclooxygenase inhibitor with the molecular formula C13H12N2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V4TKW1454M, chemically known as methanesulfonanilide, 4-nitro-2-phenoxy- but generally known as nimesulide, which bears US NIH Compound Identifier 4495. European Medicines Agency schedules Nimesulide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09294MIG.

UNSPSC 51385702 Nimesulide, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The three most recent opportunities involve naloxone and drug-deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and OTC products (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations target nimesulide specifically, and the mismatch suggests either systematic miscoding of pharmaceutical procurement or that the code itself sees minimal relevant activity. Nimesulide is a nonsteroidal anti-inflammatory drug with limited U.S. regulatory approval; state and local health systems and purchasing coalitions focus instead on broader pharmaceutical categories, opioid-reversal agents, and generic medications distributed through established wholesale channels.

The geographic spread of recent activity spans Florida, Texas, and Minnesota, with the Minnesota cooperative purchasing vehicle (MMCAP) representing a multi-state model that extends to Oregon. The Seminole County IFB (IFB60459723LAS, due July 26, 2023) sought naloxone and drug-deactivation systems through competitive bidding with quarterly deliveries and FEMA compliance requirements. The Texas HHS Commission RFI (HHS0017013, April 3, 2026) was exploratory, gathering vendor capacity information on direct-to-manufacturer prescription programs before formal procurement. The Minnesota MMCAP RFP (S1070000015802, due March 26, 2026) established multiple contracts for generic pharmaceuticals and OTC products across state and local facilities, with pricing evaluated at 75 percent weight and contract terms of two years with optional extensions. State and local procurement under this code should be monitored for actual nimesulide demand; current activity reflects no substantive market.